Results 41 to 50 of about 277,018 (298)
Targeting Bruton’s Tyrosine Kinase in CLL
Frontiers in Immunology, 2021 Targeting the B-cell receptor signaling pathway through BTK inhibition proved to be effective for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell lymphomas.
Inhye E. Ahn, Jennifer R. Brown
doaj +1 more source
Differential gene expression graphs: A data structure for classification in DNA microarrays [PDF]
, 2008 This paper proposes an innovative data structure to be used as a backbone in designing microarray phenotype sample classifiers. The data structure is based on graphs and it is built from a differential analysis of the expression levels of healthy and ...
Benso, Alfredo +3 more
core +1 more source
Translational Oncology, 2022 Tyrosine kinase inhibitors (TKIs) are established drugs in the therapy of FLT3-ITD mutated acute myeloid leukemia (AML). However, acquired mutations, such as D835 in the tyrosine kinase domain (FLT3-ITD/D835), can induce resistance to TKIs.
Kotoko Yamatani +21 more
doaj +1 more source
Race/ethnicity and the risk of childhood leukaemia: a case-control study in California. [PDF]
, 2015 BackgroundWe conducted a large registry-based study in California to investigate the association between race/ethnicity and childhood leukaemia focusing on two subtypes: acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML).MethodsWe ...
Cockburn, Myles +5 more
core +2 more sources
Anti-CD34 immunoperoxidase staining in paraffin sections of acute leukemia: Comparison with flow cytometric immunophenotyping [PDF]
Human Pathology, 1992 Anti-CD34 is a monoclonal antibody that reacts with bone marrow progenitor cells and leukemic blasts, and is expressed on 30% to 50% of all acute leukemias. Detection of CD34 has previously been restricted to flow cytometric studies. To expand the utility of CD34, we immunostained 46 paraffin-embedded bone marrow specimens with acute leukemia; results ...
Hanson, Curtis A. +2 more
openaire +3 more sources
Journal of Inflammatory Diseases, 2023 Background: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood cancer. ALL is a heterogeneous type of malignancy and treatment protocols vary based on the immunological classification of ALL. The critical step for treating ALL is to identify immunological subgroups by flow cytometry findings.
Majid Vafaie +3 more
openaire +1 more source
Leukemia Research Reports, 2014 Dual differentiation therapy with arsenic trioxide and tretinoin (all-trans-retinoic acid; ATRA) for the management of low and intermediate risk acute promyelocytic leukemia has recently been recommended by the National Comprehensive Cancer Network. Some
Morgan B. Smith +5 more
doaj +1 more source
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]
, 2019 Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M +4 more
core +1 more source
Current trends in acute leukemia: A cross-sectional survey of adult acute leukemia cases
LIAQUAT MEDICAL RESEARCH JOURNALAcute Leukemia (AL) is one of the cancer on rise globally, there is dearth of regional information in particular gender pattern of the disease among adult population from Pakistan. Therefore, this cross-sectional study was designed and conducted at Medical Oncology department at Jinnah Postgraduate Medical Center (JPMC), Karachi, Pakistan.
Sorath Bhutto +6 more
openaire +2 more sources
Haematologica, 2017 Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo +11 more
doaj +1 more source